Cited by 183SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAsthma and respiratory diseases

Eicosanoid signalling blockade protects middle-aged mice from severe COVID-19

Open access
Wong, Lok-Yin Roy, Zheng, Jian, Wilhelmsen, Kevin, Li, Kun, Ortiz, Miguel E., Schnicker, Nicholas J., Thurman, Andrew, Pezzulo, Alejandro A. +15 more·2022·Nature

Abstract

Coronavirus disease 2019 (COVID-19) is especially severe in aged populations 1. Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective, but vaccine efficacy is partly compromised by the emergence of SARS-CoV-2 variants with enhanced transmissibility 2. The emergence of these variants emphasizes the need for further development of anti-SARS-CoV-2 therapies, especially for aged populations. Here we describe the isolation of highly virulent mouse-adapted viruses and use them to test a new therapeutic drug in infected aged animals. Many of the alterations observed in SARS-CoV-2 during mouse adaptation (positions 417, 484, 493, 498 and 501 of the spike protein) also arise in humans in variants of concern 2. Their appearance during mouse adaptation indicates that immune pressure is not required for selection. For murine SARS, for which severity is also age dependent, elevated levels of an eicosanoid (prostaglandin D 2 (PGD 2)) and a phospholipase (phospholipase A2 group 2D (PLA 2 G2D)) contributed to poor outcomes in aged mice 3,4. mRNA expression of PLA 2 G2D and prostaglandin D 2 receptor (PTGDR), and production of PGD 2 also increase with ageing and after SARS-CoV-2 infection in dendritic cells derived from human peripheral blood mononuclear cells. Using our mouse-adapted SARS-CoV-2, we show that middle-aged mice lacking expression of PTGDR or PLA 2 G2D are protected from severe disease. Furthermore, treatment with a PTGDR antagonist, asapiprant, protected aged mice from lethal infection. PTGDR antagonism is one of the first interventions in SARS-CoV-2-infected animals that specifically protects aged animals, suggesting that the PLA 2 G2D-PGD 2/PTGDR pathway is a useful target for therapeutic interventions.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-022-04630-3

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Levels of PGD2 and related prostaglandins were increased in older individuals and in individuals infected with SARS-CoV-2.

    “The levels of PGD2 and related prostaglandins were also found to be increased in older individuals and in individuals infected with SARS-CoV-2 (ref.134).”

    From COVID-19 and cellular senescence (2023) · cites this paper as [134]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Wong, L.-Y. R., Zheng, J., Wilhelmsen, K., Li, K., Ortiz, M. E., Schnicker, N. J., Thurman, A., Pezzulo, A. A., Szachowicz, P. J., Li, P., Pan, R., Klumpp, K., Aswad, F., Rebo, J., Narumiya, S., Murakami, M., Zuniga, S., Sola, I., Enjuanes, L., Meyerholz, D. K., Fortney, K., McCray, P. B., & Perlman, S.
Affiliations
  • University of Iowa (US)
  • Kyoto University (JP)
  • Center for Disease Biology and Integrative Medicine, The University of Tokyo (JP)
  • Consejo Superior de Investigaciones Científicas (ES)
Corresponding author
  • McCray, Paul B.
  • Perlman, Stanley
Venue
Nature
Published
2022-03-21
Volume
605
Issue
7908
Pages
146-151
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4221027163
Cited by
178
References
49
Citations by year
2026: 21 · 2025: 34 · 2024: 59 · 2023: 43 · 2022: 21
FWCI
19.79
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
Funders
  • Cystic Fibrosis Foundation
  • Roy J. Carver Charitable Trust
  • University of Washington
  • National Institutes of Health (P30 DK, T32 AI007511, AI060699, P30 DK-54759, AI007511)
  • National Heart, Lung, and Blood Institute (K01HL140261, R01HL163024)
  • National Institute of Allergy and Infectious Diseases (T32 AI007511, P01AI060699, R01AI129269)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30-DK054759)
  • National Institute of Environmental Health Sciences (P30ES005605)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
Keywords
COVID-19 pandemic, SARS-CoV-2, prostaglandin D2, prostaglandin D2 receptor, aging, aged mice, SARS-CoV-2 variants, spike protein mutations, dendritic cells, disease severity
MeSH terms
COVID-19, SARS-CoV-2, Animals, Leukocytes, Mononuclear, Organic Chemicals, Oxazoles, Piperazines, Polyesters, Prostaglandins, Sulfonamides, Eicosanoids, Mice, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review